ORIC Pharmaceuticals Appoints Mardi C. Dier to Its Board of Directors
March 02, 2020 at 01:38 pm
Share
ORIC Pharmaceuticals, Inc. announced the appointment of Mardi C. Dier to its board of directors. Ms. Dier currently serves as executive vice president, chief financial officer and chief business officer of Portola Pharmaceuticals, Inc. Ms. Dier joined Portola in August 2006 as senior vice president and chief financial officer, has served as executive vice president and chief financial officer since November 2013, and was also appointed chief business officer in October 2018. Ms. Dier is responsible for leading the corporate finance, accounting, information technology, global supply chain, business development, investor relations, and corporate communications functions. During her tenure at Portola, she has successfully led a series of private, public, and alternative financings and helped lead the company through its pivotal transition into a commercial organization. Previously, she served as vice president of investor relations at Chiron Corporation from 2003 until its acquisition by Novartis Pharmaceuticals in 2006. Prior to joining Chiron, she worked as an investment banker at Prudential Securities, where she focused on client development, equity underwriting, and mergers and acquisitions for biotechnology and other life sciences companies, and prior to that was in the audit department of KPMG Peat Marwick.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.